SynthesisJournal of cardiothoracic surgery2026
Inhaled nitric oxide after lung transplantation: a systematic review and meta-analysis of prospective studies.
Synthesis in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung transplantation (LT) improves survival and quality of life for patients with end-stage lung disease, but ischemia-reperfusion injury (IRI) poses significant challenges. IRI leads to prolonged ICU stays and increased mortality, primarily due to primary graft dysfunction (PGD), especially grade 3 PGD. Inhaled nitric oxide (iNO), a known vasodilator and antioxidant, has been explored for the management of IRI and for mitigating PGD3 severity. Some studies recommend its preventive use; however, insufficient evidence has delayed regulatory approval.
methodsA systematic review and meta-analysis was conducted across four databases (PubMed, Scopus, Cochrane Library, and Web of Science) from inception through September 2024. Prospective studies evaluating adult lung transplant recipients who received inhaled nitric oxide (iNO) compared to a placebo or control group were included. The primary outcome was the risk of grade 3 primary graft dysfunction (PGD3). Secondary outcomes included intensive care unit length of stay (ICU-LOS), duration of mechanical ventilation (MV), and 30-day mortality. Pooled estimates for the primary analysis were calculated using a random-effects model.
resultsOut of 2,503 studies screened, six met the eligibility criteria, encompassing 420 patients. iNO was administered 12 to 48 hours post-transplant at doses of 10 to 20 ppm. There was a trend toward a lower risk of PGD3 in patients who received iNO; however, this trend failed to reach statistical significance (RR = 0.73, 95% CI = 0.45-1.19, I² = 30%). In addition, no significant differences in ICU LOS (MD = -0.21 days, 95%CI = -3.78 to 3.36, I² = 65%), mechanical ventilation duration (MD = -0.20 days, 95% CI = -0.69 to 0.28, I² = 9%), or 30-day mortality (RR =0.94, 95% CI = 0.35-2.55, I² = 0%) were observed in the random-effects analysis.
conclusionInhaled nitric oxide is well tolerated, and there is a non-significant trend toward reducing the risk of PGD3 and shortening mechanical ventilation duration. Larger, high-quality RCTs are needed to confirm these therapeutic benefits and establish definitive clinical usage guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.